CLINICAL_TRIALS
trial_result
· 2016-01-29
Clinical Trial Update: Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma [Phase 2]
Summary
Phase 2 biomarker study of elotuzumab in high-risk smoldering multiple myeloma has completed with results posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Smoldering Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2016-01-29